US FDA accepts lapses in device approval process
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has accepted that it failed to respond appropriately to “external pressure” and departed from multiple standard processes, procedures and practices while reviewing a device it approved. The device in question is Menaflex, a collagen scaffold (CS) for knee repair which is manufactured by ReGen Biologics1.